

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Carton

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cephacare flavour 250 mg tablets for dogs.
Cefalexin as cefalexin monohydrate.

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each tablet contains 250 mg cefalexin as cefalexin monohydrate.
Beef flavoured, beige speckled, flat tablets with a break mark on one side.

3. PHARMACEUTICAL FORM

Tablet

4. PACKAGE SIZE

20 tablets
100 tablets
250 tablets

5. TARGET SPECIES

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral administration.
A dose of 15 mg/kg twice daily is recommended, to be doubled where appropriate.
To enable more accurate dosing, half tablets may be used as necessary.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

See package leaflet for user warnings and disposal advice. Penicillins and cephalosporins may occasionally cause severe allergic reactions.

10. EXPIRY DATE

EXP: DD/MM/YY

Return any ½ tablet to the blister pack and use within 24 hours.

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.

Keep the blister in the outer carton.

Store in a dry place.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

See package leaflet for user warnings and disposal advice.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the sight and reach of children,

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium

16. MARKETING AUTHORISATION NUMBER

Vm 32742/4028

17. MANUFACTURER'S BATCH NUMBER

BN:

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

Blister

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cephacare flavour 250 mg tablets for dogs

250 mg cefalexin

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Ecuphar NV

3. EXPIRY DATE

EXP: DD/MM/YY

4. BATCH NUMBER

BN:

5. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET
Cephacare flavour 250 mg tablets for dogs

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
AND OF THE MANUFACTURING AUTHORISATION HOLDER
RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium

Manufacturers responsible for batch release:

Lelypharma B.V.
Zuiveringweg 42
8243 PZ
Lelystad
The Netherlands

Produlab Pharma B.V.
Forellenweg 16
4941 SJ
Raamsdonksveer
The Netherlands

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cephacare flavour 250 mg tablets for dogs.
Cefalexin as cefalexin monohydrate.

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER
INGREDIENT(S)**

Each tablet contains:
Active substance:
250 mg cefalexin as cefalexin monohydrate

Beef flavoured, beige speckled, flat tablets with a break mark on one side.

4. INDICATIONS

Treatment of infections of the respiratory tract, gastrointestinal tract, urogenital tract, the skin and localised infections in soft tissue caused by bacteria sensitive to cefalexin.

5. CONTRAINDICATIONS

Do not use in cases of known hypersensitivity to the active substance, to other cephalosporins, to other substances of the β -lactam group or to any of the excipients. Do not use in rabbits, gerbils, guinea pigs and hamsters.

6. ADVERSE REACTIONS

Vomiting has been observed occasionally in dogs when given products containing cefalexin.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For oral administration. A dose of 15 mg/kg twice daily is recommended, to be doubled where appropriate.

9. ADVICE ON CORRECT ADMINISTRATION

Cephacare flavour 250 mg tablets have a break mark on one side. To enable more accurate dosing, half tablets may be used as necessary.

Treatment for 5 days is recommended. Any increase in dose or duration of use should be according to a risk/benefit assessment by the prescribing veterinarian (e.g. in cases of chronic pyoderma).

Tablets may be added to food if necessary.

To avoid underdosing, the bodyweight should be accurately determined.

The use of cefalexin tablets of lower strengths is advised for dogs with lower bodyweights.

10. WITHDRAWAL PERIOD

Not applicable

11. SPECIAL STORAGE PRECAUTIONS

Return any ½ tablet to the blister pack and use within 24 hours.

Keep the blister pack in the outer carton.

Keep out of the sight and reach of children.

Do not store above 25°C.

Store in a dry place.

Do not use this veterinary medicinal product after the expiry date which is printed on the blister and carton after "Exp". The expiry date refers to the last day of the month.

12. SPECIAL WARNINGS

For animal treatment only. Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalexin and may decrease the effectiveness of treatment with penicillins, due to the potential for cross resistance.

In the case of an allergic reaction, treatment should be withdrawn.

The administration of cefalexin has been shown to produce no serious side-effects at many times the recommended dose rate.

As with other antibiotics which are excreted mainly by the kidneys, unnecessary accumulation may occur in the body when renal function is impaired. In cases of known renal insufficiency the dose should be reduced, antimicrobials known to be nephrotoxic should not be administered concurrently and the product should be used only according to a risk/benefit assessment by the responsible veterinarian.

The bactericidal activity of cephalosporins is reduced by concomitant administration of bacteriostatic acting compounds (macrolides, sulphonamides and tetracyclines). Nephrotoxicity can be increased when 1st generation cephalosporins are combined with polypeptide antibiotics, aminoglycosides and some diuretics (furosemide). Concomitant use with such active substances should be avoided.

The safety of the product has not been demonstrated in studies in pregnant or lactating dogs. Use only in accordance with a risk/benefit assessment by the responsible veterinarian.

User warnings

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillin may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

Do not handle this product if you know you are sensitised or if you have been advised not to be in contact with such substances.

Handle this product with great care to avoid exposure, taking all recommended precautions.

If you develop symptoms following exposure such as skin rash you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

14. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

15. OTHER INFORMATION

Cefalexin is a semi-synthetic bactericidal antibiotic belonging to the cephalosporin group which acts by interference with bacterial cell wall formation.

Cefalexin is active against a wide range of Gram-positive and Gram-negative bacteria. The following micro-organisms have been shown to be sensitive to cefalexin *in vitro*: *Staphylococcus* spp (including penicillin-resistant strains), *Streptococcus* spp, *Corynebacterium* spp, *Pasteurella multocida*, *Escherichia coli*, *Micrococcus* spp, *Moraxella* spp.

Cefalexin is resistant to the action of staphylococcal penicillinase and is therefore active against the strains of *Staphylococcus aureus* that are insensitive to penicillin (or related antibiotics such as ampicillin or amoxycillin) because of production of penicillinase.

Cefalexin is also active against the majority of ampicillin-resistant *E.coli*.

Following oral administration, cefalexin is rapidly and almost completely absorbed. Peak plasma concentrations in the dog (C_{max} = 17.49 µg/ml) are achieved within approximately 1.5 hours (T_{max} = 1.55). Cefalexin is excreted in the urine in high concentrations and has an elimination half life ($T_{1/2}$) of approximately 2.5–3 hours.

Cephacare flavour 250 mg tablets are supplied in packs of 20, 100 and 250 tablets.

Not all pack sizes may be marketed.

Prescription Only Medicine

Approved 22 June 2024
Gavin Hall